<DOC>
	<DOCNO>NCT00924664</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy tanezumab chronic low back pain . Patients randomize treated study medication previous chronic low back pain `` parent '' study eligible enroll safety extension study Preferred Rollover Time Point visit Early Termination visit parent study upon discontinuation due lack efficacy .</brief_summary>
	<brief_title>Long Term Safety Study Tanezumab Chronic Low Back Pain</brief_title>
	<detailed_description>This study terminate 30 November 2010 follow US FDA clinical hold tanezumab chronic low back pain clinical study halt dose enrollment patient 19 July 2010 potential safety issue .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>Written inform consent prior complete study procedure . Female patient must meet one follow criterion : 1 ) Female patient non childbearing potential Must post menopausal , define woman &gt; =45 year old amenorrhea 24 consecutive month ( regardless FSH level ) , woman amenorrheic least 1 year AND serum Follicle Stimulating Hormone ( FSH ) level great 30 IU/L Screening parent double blind CLBP study ; Must surgically sterile , defined hysterectomy and/or bilateral oophorectomy . 2 . ) Female patient child bear potential : must pregnant lactating , must abstinent use adequate contraception ( 2 form birth control , one must barrier method ) , must negative serum pregnancy test Screening ( within 30 day prior Baseline ) negative urine pregnancy test Baseline prior initial dose Male patient must agree female spouse / partner use adequate contraception ( 2 form birth control , one must barrier method ) non childbearing potential . Females child bear potential male must willing use approve method contraception commencement screening procedure 16 week last dose IV study medication . Patient must able comply lifestyle guideline , schedule visit , treatment plan , laboratory test , study procedure Patient treat parent tanezumab double blind CLBP study Patient complete Preferred Rollover Time Point visit double blind CLBP parent study withdraw lack efficacy . At least eight week 12 week elapse since last study medication infusion parent study . Patients permit enter extension study 12 week last dose study medication parent study ( 4 week End Treatment visit ) Failed screen parent tanezumab double blind CLBP study Withdrawn parent tanezumab double blind CLBP study adverse event Pregnant woman , lactate mother , woman suspect pregnant , woman wish become pregnant course clinical study Use investigational medication within 30 day prior Baseline ( 3 month investigational biological tanezumab ) plan receive investigational medication study medication course study Patients exit parent double blind CLBP study lack compliance , protocol violation ( include meeting entrance criterion ) , longer willing participate ( reason lack efficacy ) , lose follow parent double blind study Patients randomize parent study violation inclusion exclusion criterion withdraw parent study ; Any condition , opinion Investigator , would put patient increase safety risk otherwise make patient unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>low back pain monoclonal antibody nerve growth factor</keyword>
</DOC>